Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance agreements. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.


	Year Ended December 31,
Dollars in millions	2025		2024		2023
Revenues from alliances:
Net product sales	$	14,588	$	13,587	$	12,543
Alliance revenues	447		479		608
Total alliance revenues	$	15,035	$	14,066	$	13,151

Payments to/(from) alliance partners:
Cost of products sold	$	7,181	$	6,597	$	6,067
Selling, general and administrative	(267)		(295)		(263)
Research and development	318		237		137
Acquired IPRD	1,750		880		55
Other (income)/expense, net	(23)		(137)		(49)


	December 31,
Dollars in millions	2025		2024
Selected alliance balance sheet information:
Receivables – from alliance partners	$	198	$	221
Accounts payable – to alliance partners	1,684		1,578
Deferred income from alliances(a)	175		222


	Year Ended December 31,
Dollars in millions	2025		2024		2023
Revenues from Pfizer alliance:
Net product sales	$	14,328	$	13,187	$	12,006
Alliance revenues	115		146		200
Total revenues	$	14,443	$	13,333	$	12,206

Payments to/(from) Pfizer:
Cost of products sold – profit sharing	$	6,980	$	6,419	$	5,833
Other (income)/expense, net – amortization of deferred income	(42)		(42)		(42)


Selected alliance balance sheet information:	December 31,
Dollars in millions	2025		2024
Receivables	$	176	$	189
Accounts payable	1,599		1,463
Deferred income	95		137


	Year Ended December 31,
	2025		2024		2023
(Dollars in millions)
Net product sales	$	178	$	158	$	180
Alliance revenues	331		333		408
Total Revenues	$	510	$	491	$	588